www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products production and cash flows to commence at Canadian pharmaceutical plant
Stirling Products (ASX: STI) has begun manufacturing operations at its high-tech pharmaceutical plant in Cape Breton, Nova Scotia, enabling production and cash flows to come on stream.
The initial contract is for small runs of 300 kilograms of tableted product and further contracts are now in the process of being secured by the company.
The Canadian plant commenced first contract operations last Friday following delays to full pharmaceutical manufacturing licensing through Health Canada.
The company was required to totally re-validate all plant and equipment as well as processes and procedures in order to regain the permits.
Stirling Products will be required to obtain a Drug Identification Number (DIN) through Health Canada for each product to be manufactured.
The plant will also commence manufacturing product later this month using its existing paracetamol (acetaminophen) stock.
The 4,270 square metre pharmaceutical facility is committed to the manufacture and commercialization of prescription, over-the counter, netraceutical, and natural health products.
With current fit-out and configuration the plant has an annual capacity to manufacture and package over 550 million tablets, 5 million bottles and blend up to 1.5 million kg of product.
The commencement of manufacturing operations in Nova Scotia is a defining milestone for Stirling. It opens the door for additional contract manufacturing agreements to be won by Stirling and burgeoning cash flows to build. Today's announcement has the potential to change the fortunes for Stirling.


















